In the Oct. 9, 2026 Pharmalot column, STAT reports that Q32 Bio has appointed José Trevejo as its new chief medical officer. The item appears as part of the column’s regular coverage of industry personnel movements and the weekly spotlight on a different person.
The article presents this hiring as one of the recent comings and goings in biotechnology and pharmaceutical leadership. The published note is concise and identifies the new role without additional operational or strategic details about Q32 Bio’s plans or Trevejo’s anticipated responsibilities.
STAT’s brief profile states that José Trevejo joins Q32 Bio after serving at Enveda Therapeutics. At Enveda, he held the positions of chief medical officer and head of clinical pipeline strategy. The article does not provide further biographical information, clinical background, dates of service, or details about his accomplishments in those roles; those specifics were not reported in the source.
The Pharmalot column reiterates an open call for readers and organizations to submit notices about new hires, promotions, or positions that have been filled. STAT frames this as an inclusive prompt — asking readers, institutions, and companies to share personnel changes so they can be showcased in the regular feature. The article emphasizes that contributions are welcome and that the column will publish these items.
This item in Pharmalot is marked as a STAT+ exclusive, meaning the remainder of the story is available only to subscribers who log in. The article includes subscription prompts and pricing information, listing the plans and their costs as displayed on the site at the time of publication:
The article directs readers who already have accounts to log in, and provides calls-to-action to subscribe for access to the rest of the exclusive content and other STAT+ benefits, such as in-depth analysis, newsletters, premium events, and news alerts. The piece does not include any gated content beyond the subscription prompt in the source provided.
The column is authored by Ed Silverman, identified as Pharmalot columnist and senior writer. The byline lists the publication date as Oct. 9, 2026, and provides an email contact for the author. The article was published on the STAT website under the Pharmalot category and is presented with the site’s standard navigation and promotional material for STAT+ content.
The source includes imagery and site navigation elements typical of STAT articles, and it reiterates that the hiring notice is part of the regular weekly feature highlighting personnel moves. No additional facts, such as statements from Q32 Bio, quotations from Trevejo, or further context about the hiring decision, were reported in the source material.
The STAT source did not supply several potentially relevant details: the announcement did not include Trevejo’s start date at Q32 Bio; it did not provide a CV summary, educational or clinical qualifications; it did not quote company or individual statements; and it did not describe Q32 Bio’s therapeutic focus or the strategic rationale for the hire. Those specifics were not present in the published item.
If you have verified details about this hiring (for example, an official company announcement, a CV, or a public LinkedIn update), STAT’s column invites submission of that information for future inclusion in the feature.